We investigated the effects of centrally administered stress-related neuropeptide, angiotensin II, on the micturition reflex and the downstream signalling pathways in rats.
Introduction
Psychological stress can exacerbate lower urinary tract symptoms (LUTS), including overactive bladder and bladder pain syndrome (Merrill et al., 2013) . There is clinical evidence for a positive association between perceived psychological stress levels and urinary incontinence symptoms, with a resultant negative impact on the quality of life (Lai et al., 2015) . Children with a recent life stressor or psychiatric disorder had significantly higher LUTS scores than children without these factors (Oliver et al., 2013) . Although increasing evidence indicates that psychological stress is involved in the development of LUTS, the pathophysiological mechanism has not yet been fully clarified.
Angiotensin II (Ang II) is produced in the brain as a neurotransmitter, neuropeptide and neurohormone (Bali and Jaggi, 2013) . Ang II binds to two main receptors, the Ang II type 1 (AT 1 ) and type 2 (AT 2 ) subtypes, that are expressed in the brain (Michel et al., 2013) . Psychological stress increases Ang II, which can influence behaviour as a stress-related neuropeptide (Yang et al., 1996) . Different types of stress (isolation, immobilization/restraint, cold restraint and immunological) increase Ang II release and AT 1 receptor expression in the brain (Castren and Saavedra, 1988; Aguilera et al., 1995; Bali and Jaggi, 2013) . AT 1 receptors are widely expressed in the cortex, hippocampus, paraventricular nucleus (PVN), nucleus tractus solitaries and periaqueductal grey (PAG), which are important regions for the stress response (Castren and Saavedra, 1988; Pelegrini-da-Silva et al., 2005; Bali and Jaggi, 2013) .
Brain Ang II acts to induce several physiological responses, including stimulation of water and sodium intake, vasopressin secretion and BP increase by activating AT 1 receptors (Averill and Diz, 2000; Chen and Pan, 2007) . We also previously demonstrated that centrally administered Ang II increases the release of adrenaline from the adrenal medulla in the rat, suggesting activation of the sympathoadrenomedullary system (Nakamura et al., 2014) . Moreover, our previous findngs showed that centrally administered Ang II at a dose that does not affect BP or the peripheral adrenaline levels shortens the intercontraction interval (ICI) by acting on the brain AT 1 receptors in rats (Kawamoto et al., 2016) . However, the effect of brain Ang II on the micturition reflex and the potential signalling pathway of Ang II-induced frequent urination are unclear. A previous study showed that Ang II in the brain can modulate the activity of GABA in the CNS (Xing et al., 2009) . Since the GABAergic system is known to modulate micturition (Matsuta et al., 2010) , we investigated the effects of centrally administered Ang II on the micturition reflex and signalling pathways, focusing on the GABAergic system and AT 1 receptor downstream signalling pathway.
Methods

Animals
All animal experiments were approved by Kochi University (nos. J-46 and K-75) and were performed according to the guidelines for the care and use of laboratory animals, which conformed to the 'Guidelines for Proper Conduct of Animal Experiments' developed by the Science Council of Japan. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . All reasonable efforts were made to reduce the animals' suffering and minimize the number of animals used. A total of 204 male Wistar rats (Japan SLC Inc., Hamamatsu, Japan) weighing 340-400 g were used. The rats were purchased when they were 10 weeks old and were kept under identical temperature (20-25°C) and humidity conditions (30-70%), with ad libitum access to water and food (laboratory chow CE-2; Clea Japan, Hamamatsu, Japan). Rats were housed in groups of two per cage (width, 26.3 cm; depth, 42.6 cm; and height, 20 .2 cm) with a 14/10 h light/dark cycle. To avoid the possible influence of the oestrous cycle on micturition function in the brain, we chose to investigate male rats only. Each rat was assigned an identity number and randomized to different groups so that all experiments were carried out in a blinded manner according to a previous report (Curtis et al., 2018) . All experiments were performed under sustained anaesthesia without recovery. After each experiment, the rats were killed immediately by i.p. administration of an overdose of sodium pentobarbital (200 mg·kg À1 ). Thereafter, the rats were decapitated, and the brains were removed to confirm the exact location of the cannula inserted in the brain using cresyl violet injection.
Experimental procedures
In male Wistar rats anaesthetized with i.p. urethane (1.0 g·kg À1 ), a catheter was inserted into the bladder from the dome to perform cystometry (12 mL·h À1 saline infusion) (5200; TOP, Tokyo, Japan). The bladder catheter was connected to a pressure transducer (Kawamoto et al., 2016) . In some animals, the femoral vein was cannulated to perform i.v. drug administration, and the femoral artery was cannulated to measure BP using a PE-50 catheter connected to a pressure transducer (DX-100; Nihon Koden, Tokyo, Japan). Bladder pressure and BP were recorded by a personal computer (Macintosh G4; Apple Inc., Cupertino, CA, USA) that was connected via a bridge amplifier (ML112; AD-Instruments, Pty Ltd, Castle Hill, Australia) and a multiport controller (PowerLab/8sp; AD-Instruments, Pty Ltd) through the signal provided by the transducer. Rats were positioned on a stereotaxic frame (SR-6R; Narishige, Tokyo, Japan) and remained fixed until the end of experiments. The skull was drilled to allow for i.c.v. injection of drugs into the right lateral ventricle, which was 0.8 mm posterior to and 1.5 mm to the right of the bregma and 4.0 mm below the brain's surface (Nakamura et al., 2014; Kawamoto et al., 2016) . After the brain was stabilized for 3 h, cystometry was performed with the rats in the prone position.
Drug administration
Drugs were slowly administered into the right lateral ventricle using a cannula that was connected to a 10 μL Hamilton syringe, at a rate of 10 μL·min À1 . The cannula was retained in place for 15 min to prevent each agonist or antagonist from leaking and then removed. Each agonist or antagonist dosage for pretreatment and post-treatment was chosen in our preliminary study because each drug alone failed to affect the urodynamic parameters in rats. The current Ang II dosage for i.c.v. administration (30 pmol per rat) was chosen based on the findings of a previous study (Kawamoto et al., 2016 . Due to cannula misplacement, eight rats were excluded from the 204 rats used; therefore, data were obtained from 196 rats.
Single cystometry
In some animals, single cystometry was performed to calculate the voiding parameters before i.c.v. vehicle 1 or Ang II administration and 0-60 min afterwards, according to a previous protocol . Saline was infused into the bladder until the voiding bladder contraction peaked; then, the infusion was stopped, voided saline from the bladder was collected and voided volume (VV) was measured. The bladder was emptied to measure post-voiding residual urine volume (RV). This procedure was performed three times before vehicle 1 or Ang II (30 pmol per rat) was administered at 0-60 min afterwards. For post-experiment, bladder capacity (BC; VV + RV) and voiding efficacy (VE; VV/BC) were calculated ( Figure 1A ).
Continuous cystometry
With the remaining animals, under urethane anaesthesia continuous cystometric studies were performed to measure the ICI and maximum voiding pressure (MVP) according to our previously described methods ( Figure 
Data and statistical analyses
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology2018 (Curtis et al., 2018) . Data subjected to statistical analysis were from a group size of at least five. Additionally, the group size was determined according to the expected difference in a desired endpoint measurement from our preliminary experiment and the mean of the SDs reported in our previous reports (Kawamoto et al., 2016; Shimizu et al., 2017) . Eight rats were excluded due to cannula misplacement as described above. These data analyses were performed by an
Figure 1
Urodynamic parameters measured by single (A) or continuous (B) cystometry.
Central Ang II induces urinary frequency investigator (Y.H.) blinded to the experimental conditions. All data are expressed as means ± SEM. The values of the urodynamic parameters were calculated from the data 20 min before administration because Ang II is rapidly metabolized and has a half-life <2 min at 37°C (Anderson et al., 1993) . The relative values of the urodynamic parameters were calculated as the ratio of the average of these values measured every 20 min after the administration of each drug to the average of these values measured 20 min before administering the vehicle or Ang II. The statistical significance between the two groups was determined with Student's t-test. For analysing more than two groups, statistical differences were determined using a one-way ANOVA followed by post hoc analysis with the Bonferroni method or Tukey-Kramer test when relative data values were compared at the same time range. P values less than 0.05 indicated statistical significance. Post hoc tests were run only if F achieved P < 0.05, and there was no significant variance inhomogeneity.
Materials
We used Ang II (Peptide Institute, Osaka, Japan), telmisartan
-c]pyridine-6-carboxylic acid ditrifluoroacetate) (R&D Systems, Inc., Minneapolis, MN, USA), muscimol (muscimol hydrobromide) (5-aminomethyl-3-hydroxyisoxazole hydrobromide) (Sigma-Aldrich, St. Louis, MO, USA), baclofen (4-amino-3-(4-chlorophenyl)butanoic acid) (Wako, Osaka, Japan), U-73122 (1-[6-[[(17β)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione) (Focus Biomolecules, Plymouth Meeting, PA, USA), chelerythrine chloride (1,2-dimethoxy-N-methyl(1,3)benzodioxolo(5,6-c)phenanthr idinium chloride) (Sigma-Aldrich), apocynin (4 0 -hydroxy-3 0 -methoxyacetophenone) (AdooQ BioScience, Menlo Park, CA, USA) and tempol (1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine) (Tocris Bioscience, Bristol, UK). All other reagentgrade chemicals were obtained commercially.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c) .
Results
Centrally administered Ang II decreased the VV and BC in rats
In the single cystometry test, centrally administered Ang II (30 pmol per rat) significantly reduced the VV and BC without affecting the RV or VE for 0-60 min after administration, compared with vehicle 1 (Figure 2A-D) . The baseline values of VV (mL), RV (mL), BC (mL) and VE (%) during the À20 to 0 min period were 0.64 ± 0.05, 0.37 ± 0.11, 1.0 ± 0.09 and 68.1 ± 7.8, respectively, in the vehicle 1-treated group and 0.64 ± 0.04, 0.26 ± 0.09, 0.90 ± 0.11 and 74.2 ± 5.8, respectively, in the Ang II-treated group. There were no significant differences in the baseline values of VV, RV, BC and VE prior to drug administration between vehicle 1-treated and Ang IItreated groups.
Centrally administered Ang II shortened the ICI in rats
The results of continuous cystometry studies in rats treated with vehicle 1 or Ang II (30 pmol per rat) are shown in Figure 3 . Centrally administered vehicle 1 failed to affect the urodynamic parameters (ICI and MVP) compared with pretreatment (À20 to 0 min). However, centrally administered Ang II significantly reduced the ICI without affecting the MVP, compared with vehicle 1 (Figure 4A, B) . The central Ang II-induced effects were sustained for at least 60 min.
The baseline values of the ICI (s) and MVP (cmH 2 O) between À20 and 0 min were 186 ± 33 and 29.6 ± 4.5, respectively, in the vehicle 1-treated group and 215 ± 24 and 28.6 ± 1.4, respectively, in the Ang II-treated group. There were no significant differences in the baseline ICI or MVP values preadministration in vehicle 1-treated and Ang II-treated groups.
Figure 3
Representative in vivo continuous cystometry traces in a centrally vehicle 1 (3 μL of sterile PBS)-treated rat (A) and in an Ang II (30 pmol per rat)-treated rat (B).
Figure 4
Effects of centrally administered vehicle 1 or Ang II (30 pmol per rat) on urodynamic parameters [ICI (A) and MVP (B)] using continuous cystometry. The data are calculated as the ratio to the baseline values during the À20 to 0 min period before i.c.v. administration of Ang II and shown as means ± SEM. # P < 0.05, when relative values were compared with those of the vehicle 1-treated group using Student's unpaired t-test.
The number of animals per group is indicated in parentheses. Vehicle 1 (3 μL of sterile PBS).
Figure 5
Effects of central pretreatment with telmisartan (an AT 1 receptor antagonist), valsartan (an AT 1 receptor antagonist) or PD123319 (an AT 2 receptor antagonist) on centrally administered Ang II-induced ICI reduction using continuous cystometry. Vehicle 2 (3 μL of 10% DMF), telmisartan (3 or 10 nmol per rat), valsartan (10 nmol per rat) or PD123319 (100 nmol per rat) was administered 30 min before i.c.v. Ang II (30 pmol per rat) administration. Data were calculated as the ratio to the baseline values during the À20 to 0 min period before Ang II was administered and shown as means ± SEM. *P < 0.05, when relative values were compared with those of the vehicle 2-pretreated Ang II group using the Tukey-Kramer test. The number of animals per group is indicated in parentheses.
Central pretreatment with telmisartan or valsartan but not PD123319 suppressed central Ang II-induced ICI shortening
Central pretreatment with telmisartan (10 nmol per rat) or valsartan (10 nmol per rat) but not telmisartan (3 nmol per rat) or PD123319 (100 nmol per rat) significantly suppressed central Ang II (30 pmol per rat)-induced ICI shortening for 0-60 min, compared with the vehicle 2-pretreated Ang II (30-pmol per rat) group ( Figure 5 ).
Intravenous Ang II did not affect the urodynamic parameters
Administration of Ang II i.v. (100 and 300 pmol per rat) increased the systolic and diastolic BP ( Figure 6A , B) but did
Figure 6
Representative BP and bladder pressure recordings in an i.v. Ang II (100 and 300 pmol per rat)-treated rat (A). The effect of i.v. administered Ang II (100 and 300 pmol per rat) on BP (B). The effect of i.v. administered Ang II (100 and 300 pmol per rat) on urodynamic parameters using continuous cystometry (C). ¶ P < 0.05, compared with baseline value using post hoc analysis with the Bonferroni method. The number of animals per group is indicated in parentheses. Systolic BP (SBP) and diastolic BP (DBP): relative values of the SBP and DBP were calculated as the ratio of the average of each value measured 20 min after the i.v. Ang II administration to the average of these values measured 20 min before first i.v. Ang II administration (baseline).
Figure 7
Effect of centrally administered muscimol (a GABA A receptor agonist) (A) or baclofen (a GABA B receptor agonist) (B) using continuous cystometry. Vehicle 1 (3 μL of sterile PBS), muscimol (100, 300 or 1000 pmol per rat) or baclofen (30, 100 or 300 pmol per rat) was i.c.v. administered. Data were calculated as the ratio to the baseline values during the À20 to 0 min period before i.c.v. administration and shown as means ± SEM. # P < 0.05 when relative values were compared with those of the vehicle 1 (3 μL of sterile PBS)-treated group using the Tukey-Kramer test. The number of animals per group is indicated in parentheses. Vehicle 1 group is the same as shown in 
Effect of central pre-or post-treatment with muscimol and baclofen on central Ang II-induced ICI shortening
Centrally administered muscimol (1000 pmol per rat) or baclofen (300 pmol per rat) at the highest dose significantly extended the ICI for 0-60 min, compared with vehicle 1 treatment. However, lower doses of muscimol (100 or 300 pmol per rat) or baclofen (30 or 100 pmol per rat) failed to affect the ICI for 0-60 min, compared with vehicle 1 treatment ( Figure 7A, B) . Pretreatment with muscimol (300 pmol per rat) or baclofen (100 pmol per rat) significantly suppressed central Ang II (30 pmol per rat)-induced ICI shortening for 0-60 min, compared with vehicle 1 pretreatment ( Figure 8A ). Post-treatment with muscimol (300 pmol per rat) or baclofen (30 or 100 pmol per rat) significantly and dose-dependently prolonged central Ang II (30 pmol per rat)-induced ICI shortening for 20-60 min, compared with vehicle 1 post-treatment ( Figure 8B ).
Figure 8
The effect of central pretreatment with muscimol (a GABA A receptor agonist) or baclofen (a GABA B receptor agonist) on centrally administered Ang II-induced ICI reduction using continuous cystometry (A). Vehicle 1 (3 μL of sterile PBS), muscimol (100 or 300 pmol per rat) or baclofen (30 or 100 pmol per rat) was i.c.v. administered 30 min before i.c.v. Ang II (30 pmol per rat) administration. The effect of central post-treatment with muscimol or baclofen on centrally administered Ang II-induced ICI shortening using continuous cystometry (B). Vehicle 1, muscimol (100 or 300 pmol per rat) or baclofen (30 or 100 pmol per rat) was administered 15 min after i.c.v. Ang II (30 pmol per rat) administration. Data were calculated as the ratio to the baseline values during the À20 to 0 min period before Ang II administration and shown as means ± SEM. † P < 0.05, when relative values were compared with those of the vehicle 1-pretreated Ang II group using the Tukey-Kramer test.
‡ P < 0.05, when relative values were compared with those of the Ang II-pretreated vehicle 1 group using the Tukey-Kramer test.
Figure 9
The effect of central pretreatment with U-73122 (a PLC inhibitor) or chelerythrine chloride (a PKC inhibitor) on centrally administered Ang II-induced ICI reduction using continuous cystometry (A). Vehicle 2 (3 μL of 10% DMF), U-73122 (300 or 1000 pmol per rat) or chelerythrine chloride (300 or 1000 pmol per rat) was administered 30 min before i.c.v. Ang II (30 pmol per rat) administration. Vehicle 2 + Ang II group is the same as shown in Figure 5 
Discussion
Current data showed that centrally administered Ang II shortened the ICI without altering MVP in rats. In addition, centrally administered Ang II showed reductions in VV and BC without affecting RV or VE. These data suggested that central Ang II induces detrusor overactivity without changing voiding function. Moreover, we demonstrated the potential downstream mechanism underlying central Ang II-induced frequent urination in rats. This is the first report showing the involvement of potential AT 1 receptors in the downstream pathway (PLC/PKC/NOX/superoxide anion) and the inhibition of the GABAergic nervous system on central Ang II-induced frequent urination (Figure 10 ). Ang II is also a peptide hormone that induces vascular smooth muscle contractions and increases BP (Ito et al., 2013; Nakamura et al., 2014; Shimizu et al., 2014) . Moreover, there are some reports showing the involvement of Ang II on the activity of the lower urinary tract. A previous report showed that Ang II induces weak smooth muscle contractions via stimulation of the AT 1 receptors in rat bladders (Persson et al., 1996) . The current study showed that peripheral Ang II administration at doses that increase BP failed to affect urodynamic parameters in rats. Peripheral Ang II at the doses we used may not affect bladder contractions, at least in the acute phase. In contrast, our previous data showed that central administration of Ang II (10, 20 and 70 pmol per rat) rapidly and dose-dependently decreased the urinary bladder ICI, without altering the MVP or BP in rats (Kawamoto et al., 2016) . The current data also showed that central Ang II (30 pmol per rat) administration shortened the ICI in rats without affecting the MVP for 60 min after the central administration. Next, we performed a single cystometry because a reduction in ICI can occur not only via frequent urination but also by an increase in RV. Centrally administered Ang II showed reductions in VV and BC without affecting RV or VE compared with the vehicle-1 treatment group. These data suggested that Ang II in the brain might accelerate sensory input into the micturition centre, inducing a shortening of ICI without changing voiding function. Moreover, central Ang II-induced urodynamic phenotype changes may be similar to those induced by stress in rats because a repeated variate stress-mediated rat model showed shortened ICI without altering MVP or RV whilst awake condition (Merrill et al., 2013) . Additionally, these urodynamic changes are also similar to several other animal models of stress such as social defeat, nontraumatic immobilization/restrain and water avoidance stress (Chang et al., 2009; Wood et al., 2009; Smith et al., 2011) . Therefore, psychological stressinduced central Ang II production might be involved in psychological stress-induced bladder dysfunction such as increased urinary frequency and urgency (Smith et al., 2011; Merrill et al., 2013) . The current study also showed that centrally administered AT 1 receptor antagonists (telmisartan or valsartan) but not an AT 2 receptor antagonist (PD123319) suppressed central Ang II-induced shortening of ICI in the rat. These data support our previous report showing that centrally administered Ang II induces frequent urination by acting on brain AT 1 receptors (Kawamoto et al., 2016) .
Next, we examined the potential downstream mechanism underlying central Ang II-induced frequent urination in rats. Some functional brain imaging studies demonstrated that many brain structures are involved in the micturition reflex (DasGupta et al., 2007; Fowler et al., 2008; Kitta et al., 2015) . These data showed that the thalamus, insula, prefrontal cortex, anterior cingulate, PAG, pons, medulla and supplementary motor area are activated during the urinary storage (DasGupta et al., 2007; Fowler et al., 2008; Kitta et al., 2015) . PAG is the grey matter located in the midbrain, and it regulates the Barrington's nucleus (pontine micturition centre)-related micturition reflex (Benarroch, 2012) . PAG is also controlled by many brain structures, such as the prefrontal cortex, anterior cingulate, insula, hypothalamus, basal ganglia and cerebellum. The PVN is located in the hypothalamus and an important brain region for stress response (Ishizuka et al., 2000) . The PVN also directly influences the PAG through these nervous fibres (Pittman et al., 1981) . There are some reports about the interaction between the Ang II and the GABAergic system in the PAG and PVN (Li et al., 2003; Xing et al., 2009; Stone et al., 2011) . Central Ang II inhibits the release of GABA in the PAG through the activation of presynaptic AT 1 receptors (Xing et al., 2009) . Another study reported that Ang II attenuates the GABAergic synaptic input into the PVN of the hypothalamus by activating presynaptic AT 1 receptors, thereby exciting neuronal activity (Li et al., 2003) . GABA is an important inhibitory neurotransmitter in the CNS. I.c.v. administration of muscimol or baclofen increases BC and inhibits the micturition reflex in normal rats (Kanie et al., 2000) . Microinjections of muscimol into the caudal ventrolateral PAG suppressed the micturition reflex in rats under urethane anaesthesia (Stone et al., 2011) . We showed that a higher dose of centrally administered muscimol (1000 pmol per rat) or baclofen (300 pmol per rat) extended the ICI in control rats, which is similar to a previous study (Kanie et al., 2000) . Therefore, stimulating the GABAergic nervous system may inhibit the micturition reflex. Centrally administered muscimol (300 pmol per rat) or baclofen (100 pmol per rat) did not affect ICI in rats. However, muscimol (300 pmol per rat) or baclofen (100 pmol per rat) pretreatment significantly suppressed centrally administered Ang II-induced frequent urination. Muscimol (300 pmol per rat) or baclofen (30 or 100 pmol per rat) post-treatment also suppressed centrally administered Ang II-induced shortening of ICI. Considering these previous reports, the current data suggest that Ang II in the brain may lead to an increase in frequent urination via inhibition of the GABAergic nervous system. Furthermore, we investigated the involvement of AT 1 receptor signalling pathway in the Ang II-induced frequent urination. Ang II activates the canonical G q protein/PLC/PKC and NOX signalling pathways in various tissues through stimulation of the AT 1 receptors (Cohn et al., 2007; Inoue et al., 2012) . This signalling pathway produces ROS, including superoxide anion. The current study showed that central pretreatment with U-73122, chelerythrine chloride, apocynin or tempol dosedependently inhibited central Ang II-induced frequent urination. These data indicate the involvement of the AT 1 receptor, PLC, PKC, NOX and ROS including superoxide anion on central Ang II-induced frequent urination. Although no report has evaluated the role of ROS including superoxide anion in the brain on the micturition reflex, ROS act as intracellular messengers of many of the physiological and pathological effects of circulating Ang II in the brain (Zimmerman et al., 2002; Israel et al., 2009) . Several studies have evaluated ROS involvement in GABA release. A previous report showed that central Ang II attenuates GABAergic input in the PVN presympathetic neurons through ROS, especially superoxide anions (Chen and Pan, 2007) . Moreover, ROS in the spinal cord contribute to neuropathic pain by reducing the inhibitory influence of GABA (Yowtak et al., 2011) . In other areas of research, the central Ang II signalling pathway (increases in ROS, followed by decreasing GABAergic transmission) within the PVN has been reported to regulate sympathetic nerve activity in chronic heart failure (Xu and Li, 2015) . Current and previous data suggest that central Ang II-induced frequent urination may at least be partially attributed to the ROS-mediated inhibition of GABA neuron activity in rats (Figure 10) . Thus, blocking AT 1 receptors in the brain could be a useful target for psychological stress-induced detrusor overactivity.
AT 1 receptor antagonists are commonly used as antihypertensive drugs in the clinic . Also, AT 1 receptor antagonists might be effective drugs for LUTS patients. Previous clinical evidence showed that AT 1 receptor antagonists significantly decreased the storage and voiding symptoms in male hypertension patients (Ito et al., 2013) . Interestingly, other anti-hypertensive drugs (ACE inhibitors and calcium channel blockers) failed to improve these urodynamic parameters (Ito et al., 2013) . Our previous report also showed that chronic treatment with the AT 1 receptor antagonist olmesartan ameliorates detrusor overactivity in spontaneously hypertensive rats via an increase in bladder blood flow ). An increase in bladder blood flow induced by an AT 1 receptor antagonist is one of the possible target mechanisms against detrusor overactivity. However, the pharmacological targeting mechanism is not well clarified. Some AT 1 receptor antagonists (telmisartan and candesartan) were reported to be able to pass through the blood-brain barrier and were speculated to block AT 1 receptors in the brain (Gohlke et al., 2001; Braszko et al., 2013) . A clinical study also showed that telmisartan has beneficial effects on cognitive and regional cerebral blood flow in elderly hypertensive patients with Alzheimer's disease (Kume et al., 2012) . These data suggest that AT 1 receptor antagonists, which penetrate the blood-brain barrier, might improve detrusor overactivity via blocking AT 1 receptors in the brain.
Our study's main limitation is that cystometry was performed under anaesthesia, using urethane, and urethane alone has been reported to affect urodynamic recordings and neurotransmitter levels in rodent models (Yoshiyama et al., 1994; Chang and Havton, 2008) . Similar experiments should be conducted in awake animals. Another limitation of the study is that the precise brain region or nucleus, which central Ang II facilitates the micturition reflex, has not been clarified. According to a previous study and our current data, the possible targets are the PAG or PVN. Further studies are necessary to elucidate this point.
In summary, we demonstrated that Ang II in the CNS may facilitate the micturition reflex by inhibiting the brain's GABAergic nervous system and stimulating the AT 1 receptor/PLC/PKC/NOX/superoxide anion pathway.
